| Jul 1, 2024 | Third Arc Bio | $170.0M Series A | Vida Ventures, Cormorant Asset Management, Hillhouse Capital Group | Sofinnova Investments, AbbVie Ventures, abrdn, BVF Partners, Foresite Capital, Freepoint Capital Group, Goldman Sachs, Janus Henderson Investors, Logos Capital, Marshall Wace, Francesco Draetta, Loretta Tse, T. Rowe Price Associates |
| Jan 1, 2023 | Amolyt Pharma | $140.0M Series C | Toby Sykes, Cédric Moreau | Andera Partners, Bioqube Ventures, Domain Associates, EQT Life Sciences, Forbion, Kurma Partners, Pontifax Venture Capital, Sanofi Ventures, Ysios Capital, Vincent Brichard, ATEM Capital, Bpifrance, Credit Agricole Creation, CTI Life Sciences Fund, LSP, Mass General Brigham Ventures, Novo Holdings, OrbiMed, Relyens Innovation Sant, Sectoral Asset Management |
| May 1, 2022 | Invetx | $61.0M Series B | Eight Roads Ventures, Jessica Alston, Google Ventures, Novo Holdings | Anterra Capital, F-Prime Capital Partners, Casdin Capital |
| Feb 1, 2022 | Endeavor BioMedicines | $100.0M Series B | Andrew Lam, Andrew Lam, Monal Mehta | Atlas Venture, Hatteras Venture Partners, Omega Funds, RA Capital, Roche Venture Fund, Patrick Enright, Perceptive Advisors, Piper Heartland Healthcare Capital, Revelation Partners, T. Rowe Price Associates |
| Nov 9, 2021 | Arbor Biotechnologies | $215.0M Series B | Frank Yu, Chen Yu, Temasek | ARCH Venture Partners, ArrowMark Partners, Deep Track Capital, GreatPoint Ventures, Illumina Ventures, Janus Henderson Investors, Logos Capital, Ono Venture Investment, Piper Heartland Healthcare Capital, Ridgeback Capital Investments, Section 32, Surveyor Capital, Tao Capital Partners, T. Rowe Price Associates, Vertex, Woodline Partners |
| Nov 3, 2021 | Parthenon Therapeutics | $65.0M Series A | Northpond Ventures, Taiho Ventures | Alexandria Venture Investments, Breakout Ventures, Creacion Ventures, KdT Ventures, Park West Asset Management, Section 32 |
| Nov 1, 2021 | Quell Therapeutics | $160.0M Series B | Fidelity Management & Research Company, Rachel Mears, Wayne Holman, Houman Ashrafian | Lightstone Ventures, Soffinova Partners, SV Health Investors, Judith Hartley MBE, Janus Henderson Investors, Monashee Investment Management, Point72, Martin Murphy |
| Nov 1, 2021 | HotSpot Therapeutics | $100.0M Series C | Pivotal bioVenture Partners | AbbVie Ventures, Access Biotechnology, Atlas Venture, EQT Life Sciences, Novo Ventures, RiverVest, Roche Venture Fund, Samsara BioCapital, Soffinova Partners, SR One, B Capital Group, CaaS Capital Management, Fouad Azzam, Ph.D., Monashee Investment Management, MRL Ventures Fund, Pavilion Capital, Revelation Partners |
| Oct 1, 2021 | ReCode Therapeutics | $80.0M Series B | Oleg Nodelman | Bioluminescence Ventures, InterWest, MPM Capital, OrbiMed, Pfizer Venture Investments, Polaris Partners, Vida Ventures, Sam Altman, Colt Ventures, Hunt Technology Ventures, NS Investment, Osage University Partners, Sanofi Ventures, Superstring Capital |
| Jul 27, 2021 | Aristea Therapeutics | $63.0M Series B | Fidelity Management & Research Company | Maurice Mezzino, Novo Holdings, Loretta Tse |
| Jun 1, 2021 | ImmuneID | $50.0M Series A | Alta Partners | Advanced Technology Ventures, Aisling Capital, Chris, Domain Associates, Longwood Fund, Section 32, The Column Group, Third Rock Ventures, Alexandria Venture Investments, ARCH Venture Partners, In-Q-Tel, Pitango HealthTech, Redwood Capital Investments, Xfund |
| May 22, 2021 | HiberCell | $97.4M Debt / Series B | — | ARCH Venture Partners, Bristol Myers Squibb, Hercules Capital, Huizenga Capital Management, Magnetic Ventures, Rene Mora, Mount Sinai Innovation Partners, Trinitas Capital |
| May 20, 2021 | Biotheryx | $92.0M Series E | Farallon Capital Management | Alexandria Venture Investments, Avidity Partners, Deep Track Capital, Irving Investors, Janus Henderson Investors, Lumira Ventures, Point72, Rock Springs Capital, Surveyor Capital, Wedbush Healthcare Partners |
| May 1, 2021 | Oculis | $57.0M Series C | BVCF (Bioveda China Fund), Dr. Sylvia Xin He | Zhi Yang, Kiersten Stead, Dimension Capital, Earlybird Venture Capital, Eclipse Ventures, EQT Life Sciences, Longitude Capital, Maveron, New Enterprise Associates (NEA), OrbiMed, Peterson Ventures, Pivotal bioVenture Partners, The Column Group, Farzad Nazem, Bay City Capital, Brunnur Ventures, Nan Fung Life Sciences, Novartis, Silfurberg, VI Partners, Wille Finance |
| Mar 1, 2021 | Caribou Biosciences | $120.0M Series C | Farallon Capital Management, Santhosh Palani, PhD, CFA, Jeffrey Long-McGie | 1435 Capital Management, 6th Man Ventures, Afore Capital, DFJ, E1 Ventures, Flucas Ventures, Founders Co-op, Heavybit, Invariantes Fund, Kleiner Perkins, KRM Interests LLC, LombardStreet Ventures, Maverick Capital, Menlo Ventures, Mouro Capital, Necessary Ventures, QED Investors, Robert Bosch Venture Capital, Starbridge Venture Capital, Sterling Equity, William Guo, XStarPartners, Adam Marchick, Andy Rubin, Dylan Taylor, hugo angelmar, Ravi Grover, Richard Cooperstein, Rob Meyerson, Sri Batchu, Sung ho Choi, AbbVie Ventures, Adage Capital Management, Avego Bioscience Capital, Avidity Partners, Heritage Medical Systems, Invus, Janus Henderson Investors, LifeSci Venture Partners, Maverick Ventures, Monashee Investment Management, Point72, Pontifax, The Leukemia & Lymphoma Society |
| Mar 1, 2021 | Pyxis Oncology | $150.0M Series B | Christian Schetter, gotham makker | Pfizer Venture Investments, Acuta Capital Partners, Agent Capital, BVF Partners, Cormorant Asset Management, HBM Healthcare Investments, Janus Henderson Investors, Laurion Capital Management, Leaps by Bayer, LifeSci Venture Partners, Logos Capital, Longwood Fund, Perceptive Advisors, RA Capital Management, Ridgeback Capital Investments, Surveyor Capital |
| Oct 1, 2020 | Priothera | $35.0M Series A | HealthCap, Manus Rogan | Earlybird Venture Capital, EQT Life Sciences, Forbion, INKEF Capital, Pontifax Venture Capital, Vivo Capital, Henry Skinner |
| Sep 1, 2020 | Invetx | $10.0M Series A | Anterra Capital | AbCellera, Casdin Capital, WuXi Biologics |
| May 1, 2020 | HotSpot Therapeutics | $65.0M Series B | SR One | AbbVie Ventures, Access Biotechnology, Atlas Venture, Novo Ventures, RiverVest, Roche Venture Fund, Soffinova Partners, Brace Pharma Capital, MRL Ventures Fund, Solasta Ventures, Henry Skinner |
| Apr 2, 2020 | Dynacure | $54.5M Series C | Ellen Hukkelhoven | Andera Partners, Laurent Higueret, Kurma Partners, Pontifax, Henry Skinner |
| Apr 1, 2020 | Rallybio | $150.0M Series B | Pivotal bioVenture Partners | Canaan Partners, HealthQuest Capital, Sofinnova Investments, 5AM Ventures, Canaan Partners, Connecticut Innovations, Fairview Capital, F-Prime Capital, Mitsui & Co. Global Investment, New Leaf Venture Partners, Solasta Ventures, TPG, Viking Global Investors |
| Nov 1, 2019 | Arkuda Therapeutics | $44.0M Series A | Atlas Venture | EQT Life Sciences, Pivotal bioVenture Partners, Soffinova Partners, SR One, Mission BioCapital |
| Sep 24, 2019 | Amphivena Therapeutics | $62.0M Series C | NanoDimension, Qiming Venture Partners USA | Franklin Berger, AJU IB Investment, Industrial Investors, Kaitai Capital, Korys Merieux, MPM Capital, Nawton Limited |
| Jan 1, 2019 | Oculis | $16.0M Series B | Henry Skinner | Eclipse Ventures, Longitude Capital, Maveron, New Enterprise Associates (NEA), Peterson Ventures, Pivotal bioVenture Partners, Farzad Nazem, Peter Bisgaard |
| Oct 25, 2018 | Milestone Pharmaceuticals | $80.0M Other Equity | RTW Investments | BDC Capital, Boxer Capital, Domain Associates, Forbion, Go Capital, Novo Holdings, Pappas Capital, Venrock |
